- Home
- CYRX vs MREO Comparison
CYRX vs MREO Comparison
Compare CYRX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | MREO |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United Kingdom |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.6M | 67.5M |
| IPO Year | 2008 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CYRX | MREO |
|---|---|---|
| Price | $8.05 | $0.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $12.94 | $3.90 |
| AVG Volume (30 Days) | 382.2K | ★ 1.8M |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $9.71 | N/A |
| Revenue Next Year | $9.56 | $6,363.05 |
| P/E Ratio | $5.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.63 | $0.20 |
| 52 Week High | $11.45 | $2.94 |
Technical Indicators
Market Signals| Indicator | CYRX | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 42.00 |
| Support Level | $6.57 | $0.35 |
| Resistance Level | $9.32 | $0.45 |
| Average True Range (ATR) | 0.45 | 0.03 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 22.57 | 70.30 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).